On June 7, 2024, Jiangsu Zhonghui Yuantong Bio-technology Co., Ltd (hereinafter referred to as “Zhonghui Bio”) declared that the application for “Influenza Virus Subunit Vaccine” was accepted by the Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (CDE)..

2024年6月7日，江苏中汇元通生物科技有限公司（以下简称“中汇生物”）宣布“流感病毒亚单位疫苗”申请已被国家药品监督管理局（CDE）药物评价中心受理。。

Source: State Drug Administration Drug Evaluation Center Government Service Website

资料来源：国家药品监督管理局药品评估中心政府服务网站

About Influenza Virus Subunit Vaccine

关于流感病毒亚单位疫苗

At present, influenza virus is still one of the important respiratory pathogens threatening human public health, seasonal influenza outbreaks or occasional cross-species transmission of influenza viruses and pandemics to human health and socio-economic impact of the WHO position paper on influenza vaccination and the Chinese Center for Disease Control and Prevention of the Chinese influenza vaccine prevention and vaccination technical guidelines clearly put forward, the annual influenza vaccine is the most cost-effective measures to prevent influenza, which can significantly reduce the incidence of influenza.

目前，流感病毒仍然是威胁人类公共健康的重要呼吸道病原体之一，季节性流感爆发或流感病毒偶尔跨物种传播和大流行对人类健康和社会经济的影响，世界卫生组织关于流感疫苗接种的立场文件和中国疾病预防控制中心对中国流感疫苗预防接种技术指南明确提出，每年接种流感疫苗是预防流感最具成本效益的措施，可以显著降低流感发病率。

The WHO position paper on influenza vaccination and the Chinese Center for Disease Control and Prevention (CDC) Technical Guidelines for Influenza Vaccination in China clearly state that annual influenza vaccination is the most cost-effective measure to prevent influenza, and it can significantly reduce the risk of influenza and serious complications..

世卫组织关于流感疫苗接种的立场文件和中国疾病预防控制中心（CDC）中国流感疫苗接种技术指南明确指出，每年接种流感疫苗是预防流感最具成本效益的措施，可以显着降低患流感和严重并发症的风险。。

This year, WHO suggested that after March 2020, the global influenza surveillance network had not detected the B/Yamagata virus, and therefore recommended that the influenza vaccine should no longer include the B/Yamagata lineage component. CWB responded positively and acted quickly to complete the declaration of the influenza virus subunit vaccine and realize the product launch as soon as possible, so as to scientifically respond to the prevention and control of influenza and provide a variety of influenza vaccine choices for the society..

今年，世卫组织建议，2020年3月后，全球流感监测网络尚未检测到B/山形病毒，因此建议流感疫苗不再包括B/山形谱系成分。CWB积极响应，迅速行动，完成流感病毒亚单位疫苗申报，尽快实现产品上市，科学应对流感防控，为社会提供多种流感疫苗选择。。

CWB has always insisted on not making simple copies, and has plowed into the field of subunit influenza technology. Up to now, the subunit influenza vaccine family of Zhonghui Biotechnology includes: quadrivalent influenza virus subunit vaccine for people aged 6-35 months, quadrivalent influenza virus subunit vaccine for people aged 3 years and above, quadrivalent influenza virus subunit vaccine (adjuvant) for the elderly, trivalent influenza virus subunit vaccine, trivalent influenza virus subunit vaccine (adjuvant) for the elderly, as well as general subunit influenza vaccines under development, precisely covering the needs of various groups of people.

CWB一直坚持不制作简单的拷贝，并已涉足亚单位流感技术领域。截至目前，中汇生物科技流感亚单位疫苗家族包括：6-35个月四价流感病毒亚单位疫苗、3岁及以上四价流感病毒亚单位疫苗、老年四价流感病毒亚单位疫苗（佐剂）、三价流感病毒亚单位疫苗、老年三价流感病毒亚单位疫苗（佐剂）以及正在开发的一般亚单位流感疫苗，精确覆盖了各类人群的需求。

These vaccines precisely cover the needs of various groups of people. Among them, the quadrivalent influenza virus subunit vaccine (Huilkangxin HRK-X®) for people aged 3 years and above has been marketed and sold, and has been well received by vaccine recipients for its high purity, low side effects of inoculation, good safety, and comprehensive protection.

这些疫苗正好能满足不同人群的需求。其中，针对3岁及以上人群的四价流感病毒亚单位疫苗（Huilkangxin HRK-X®）已上市销售，因其纯度高，接种副作用低，安全性好，受到疫苗接种者的欢迎。全面保护。

Zhonghui Bio will also adhere to the principles of innovation-driven, quality-leading, and realize the marketing and sales of all varieties of influenza vaccine products as soon as possible, contributing more to the prevention and control of influenza with Zhonghui's power!.

中汇生物还将坚持创新驱动、质量领先的原则，尽快实现各种流感疫苗产品的营销和销售，以中汇的力量为流感防控做出更多贡献！。

Imagine with a 3-stage amplification circuit, with a 2-stage active filter amplification loop, amplified the signal at the same time will also amplify the noise, if the noise is not a significant departure from the useful signal spectrum, then no matter how to filter both at the same time to amplify the results of the signal-to-noise ratio did not improve.

想象一下，用一个3级放大电路，用一个2级有源滤波器放大回路，放大信号的同时也会放大噪声，如果噪声没有明显偏离有用的信号频谱，那么无论如何滤波，两者同时放大的结果信噪比都没有提高。

Therefore, the rope (line) encoder, rope displacement sensor, linear displacement sensor circuit must be refined and simple. Can save a resistor or capacitor must be removed. This is many engineers who design sensors are easy to ignore the problem. The known situation is that the sensor circuit with the problem of noise plagued, the more the circuit is modified the more complex, becoming a strange circle..

因此，绳（线）编码器、绳位移传感器、线位移传感器电路必须精巧、简单。可以节省的电阻器或电容器必须拆下。这是许多设计传感器的工程师容易忽视的问题。已知的情况是，传感器电路存在噪声问题，电路修改得越多越复杂，变成一个奇怪的圆圈。。